Press Releases Fortress Biotech, Inc.

Equities

FBIO

US34960Q3074

Market Closed - Nasdaq Other stock markets 01:30:00 10/05/2024 am IST			5-day change	1st Jan Change
1.71 ^USD	-2.29%		-5.00%	-43.19%

03/04	North American Morning Briefing : Powell Awaited -2-	DJ
02/04	Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024	07/05	AQ
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer	02/05	AQ
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	29/04	AQ
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024	25/04	AQ
Avenue Therapeutics Announces Reverse Stock Split	24/04	AQ
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights	29/03	AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	26/03	AQ
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	22/03	AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	18/03	AQ
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	15/03	AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	13/03	AQ
Fortress Biotech to Participate in 36th Annual ROTH Conference	12/03	AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	11/03	AQ
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease	04/03	AQ
Lindsay RosenwaldÃ¢€™s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries	03/02	AQ
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea	05/01	AQ
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	04/01	AQ
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy	03/01	AQ
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million	03/01	AQ
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	29/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Fortress Biotech, Inc.

Equities

FBIO

US34960Q3074

Press Releases

Filters